Quick Answer
Dianthus Therapeutics, Inc. /DE/ reported Revenue From Contract With Customer Excluding Assessed Tax of $2.04 million for the year ending 2025.
- Dianthus Therapeutics, Inc. /DE/ showed a decrease of -67.3% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Dianthus Therapeutics, Inc. /DE/'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2022: $1.17 million | Q3 2023: $924.0 thousand | Q1 2024: $874.0 thousand | Q2 2024: $1.86 million | Q3 2024: $2.17 million | Q1 2025: $1.16 million | Q2 2025: $193.0 thousand | Q3 2025: $396.0 thousand.
- Over the full 3 years of available data (2023 to 2025), Dianthus Therapeutics, Inc. /DE/'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 28.0%.
- Historical annual values: Fiscal year 2025: $2.04 million | Fiscal year 2024: $6.24 million | Fiscal year 2023: $2.83 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: